4.6 Article

Excellent leukemia control after second hematopoietic cell transplants with unrelated cord blood grafts for post-transplant relapse in pediatric patients

Related references

Note: Only part of the references are listed.
Article Hematology

T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancy

Claire Horgan et al.

Summary: Stem cell transplant outcomes for high-risk and relapsed/refractory pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) have historically been poor. Cord blood (CB) transplant with T-cell repletion enables enhanced graft-versus-leukemia effect. This study analyzed data from 367 patients undergoing CB transplant or other cell source transplant for pediatric AML/MDS in the UK and Ireland, showing that CB transplant had improved event-free survival, reduced chronic graft-versus-host disease, and possibly improved overall survival, regardless of measurable residual disease (MRD) status. CB transplant without serotherapy may be the optimal option for children with myeloid malignancies.

BLOOD ADVANCES (2023)

Article Hematology

Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non-remission acute myeloid leukaemia: A nationwide retrospective study

Kensuke Matsuda et al.

Summary: A study conducted using data from the Japanese nationwide transplantation registry found that haplo-HSCT and CBT showed comparable outcomes as the first transplant treatment for non-remission AML patients.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Biophysics

Outcomes of pediatric patients who relapse after first HCT for acute leukemia or MDS

Akshay Sharma et al.

Summary: Disease relapse remains a major cause of treatment failure in patients undergoing alloHCT for high-risk acute leukemias or MDS. Comprehensive data on outcomes post-transplant relapse, especially in pediatric patients, are lacking. The study suggests that receiving a second alloHCT or having a longer interval between alloHCT and relapse may improve overall survival rates.

BONE MARROW TRANSPLANTATION (2021)

Review Hematology

Current status of umbilical cord blood transplantation in children

Maria Gabelli et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Editorial Material Oncology

Treosulfan-based conditioning in HSCT patients

Paul Veys et al.

PEDIATRIC HEMATOLOGY AND ONCOLOGY (2020)

Article Hematology

Guidelines for Cord Blood Unit Selection

Ioannis Politikos et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)

Review Biotechnology & Applied Microbiology

Cord blood transplantation for acute leukemia

Mattia Algeri et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2020)

Article Hematology

Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia

Troy C. Lund et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

Article Oncology

Second allogeneic hematopoietic cell transplantation for relapse after first allografts

Boglarka Gyurkocza et al.

LEUKEMIA & LYMPHOMA (2019)

Article Hematology

Reduction in Mortality after Umbilical Cord Blood Transplantation in Children Over a 20-Year Period (1995-2014)

Lisa P. Spees et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

Article Hematology

Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies

Juliet N. Barker et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)

Editorial Material Hematology

The power of cord blood cells

Jaap Jan Boelens

BLOOD (2016)

Article Medicine, General & Internal

Cord-Blood Transplantation in Patients with Minimal Residual Disease

Filippo Milano et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Editorial Material Hematology

Cord blood T cells are completely different

Juliet Barker et al.

BLOOD (2015)